Osteologix to Present a Corporate Overview and Phase 2 Osteoporosis Data at the BIO International ConferenceGLEN ALLEN, Va.--(BUSINESS WIRE)--June 17, 2008 - Osteologix, Inc. (OTCBB: OLGX) today announced that the Company will make two presentations focused on the Company's lead osteoporosis drug candidate, NB S101, at the Biotechnology Industry Organization (BIO) International Convention on June 17 and June 18, 2008 at the San Diego Convention Center.
On Tuesday, June 17, at 3:15 p.m. PDT, Baxter Phillips, III, Senior Director of Corporate Development at Osteologix, will present a corporate overview on the NB S101 development program during the BIO International Convention Business Forum.
On Wednesday, June 18, the Company will present the poster entitled, "Effect of Three Doses of Strontium Malonate (NB S101) on Markers of Bone Turnovers and Bone Mineral Density: The STRONG Study". The poster presentation, which was selected for the Innovative Corridor Session, demonstrates that NB S101 (strontium malonate) achieved statistical significance in reaching its primary endpoint which measured the drugs ability to suppress bone resorption. In addition, NB S101 demonstrated a significant improvement in bone mineral density (BMD) at 12 weeks. The drug was well-tolerated at all dose levels. The poster is available at the company's corporate website, www.osteologix.com.
BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,150 corporate members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. BIO's mission is to be the champion of biotechnology and the advocate for our member organizations--both large and small.
Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis, by developing innovative therapies. Its lead investigational product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
Forward Looking Statements
Certain of the statements set forth in this press release constitute "Forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may" "project," "plan," "will," "should," "could," "would," or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix's research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.
Investors and Media:
Baxter Phillips, III, 804-747-6026
Sr. Director, Corporate Development
Posted: June 2008